Oral Calcium in Pregnant Women With Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

1993-08-31

Study Completion Date

1999-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine of providing calcium supplementation to women with pre-existing hypertension reduces the level of blood pressure, requirement for antihypertensive drugs, and incidence of pre-eclampsia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Calcium for Pre-Eclampsia Prevention (CPEP)

NCT00000534

Cardiovascular Diseases Eclampsia Heart Diseases +5 more

COMPLETED PHASE3

Calcium Intake, Metabolism, and Gestational Blood Pressure

NCT00005206

Cardiovascular Diseases Heart Diseases

COMPLETED

Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China

NCT01806454

Preeclampsia

UNKNOWN NA

Low Dose Calcium to Prevent Preeclampsia

NCT02338687

Pre-Eclampsia Hypertension, Pregnancy-Induced Dietary Calcium Deficiency

COMPLETED PHASE4

Role of L-citrulline in Prevention of Pregnancy Associated Hypertension

NCT04979793

Pregnancy Induced Hypertension Preeclampsia and Eclampsia Gestational Hypertension

SUSPENDED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BACKGROUND:

Maternal and fetal complications are more likely to occur in pregnant women with preexisting hypertension. Alterations in calcium metabolism, the renin angiotensin system, and intracellular free calcium concentration have been identified in this high risk population. The beneficial effects of calcium supplementation on blood pressure and the incidence of superimposed pre-eclampsia may be due to correction of the hormonal and cellular basis for vasoconstriction. The trial sought to prove that oral calcium lowered parathyroid hormone, reduced intracellular free calcium, and decreased vascular endothelin production, resulting in vasodilation and compensatory stimulation of the renin-angiotensin system.

DESIGN NARRATIVE:

Randomized. Double blind. In this observational study, subjects were assigned to two grams of supplemental elemental calcium or to placebo at 13 to 15 weeks gestation. The trial determined the effect of oral calcium supplementation on: the level of blood pressure; the need for antihypertensive drugs; forearm and peripheral vascular resistance; the incidence of maternal complications, including pre-eclampsia and eclampsia; and plasma levels of vitamin D3, ionized calcium, parathyroid, renin activity, angiotensin II, endothelin, nitrate/nitrite, prostacyclins, and intracellular calcium concentrations in lymphocytes and platelets. These variables were measured prior to randomization and every two months throughout pregnancy and the postpartum. Support ended in July 1999.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.